BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27807828)

  • 21. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
    Zhao Y; Wang Z; Jiang Y; Yang C
    Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Annexin A7 deficiency potentiates cardiac NFAT activity promoting hypertrophic signaling.
    Voelkl J; Alesutan I; Pakladok T; Viereck R; Feger M; Mia S; Schönberger T; Noegel AA; Gawaz M; Lang F
    Biochem Biophys Res Commun; 2014 Feb; 445(1):244-9. PubMed ID: 24508799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significant allelic loss of ANX7region (10q21) in hormone receptor negative breast carcinomas.
    Leighton X; Srikantan V; Pollard HB; Sukumar S; Srivastava M
    Cancer Lett; 2004 Jul; 210(2):239-44. PubMed ID: 15183540
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TIA1 interacts with annexin A7 in regulating vascular endothelial cell autophagy.
    Huang S; Liu N; Li H; Zhao J; Su L; Zhang Y; Zhang S; Zhao B; Miao J
    Int J Biochem Cell Biol; 2014 Dec; 57():115-22. PubMed ID: 25461769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of annexin A7 gene and protein induces the apotosis and decreases the invasion, migration of the hepatocarcinoma cell line.
    Huang Y; Wang Q; Du Y; Bai L; Jin F; Zhang J; Fan S; Wang H; Song L; Gao Y; Wang X; Tang J
    Biomed Pharmacother; 2014 Sep; 68(7):819-24. PubMed ID: 25070395
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclin E and FGF8 are downstream cell growth regulators in distinct tumor suppressor effects of ANXA7 in hormone-resistant cancer cells of breast versus prostate origin.
    Bera A; Leighton XM; Pollard H; Srivastava M
    Trends Cancer Res; 2018; 13():55-62. PubMed ID: 30369774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression.
    Kechagioglou P; Papi RM; Provatopoulou X; Kalogera E; Papadimitriou E; Grigoropoulos P; Nonni A; Zografos G; Kyriakidis DA; Gounaris A
    Anticancer Res; 2014 Mar; 34(3):1387-400. PubMed ID: 24596386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of annexin A7 leads to alterations in frequency-induced shortening of isolated murine cardiomyocytes.
    Herr C; Smyth N; Ullrich S; Yun F; Sasse P; Hescheler J; Fleischmann B; Lasek K; Brixius K; Schwinger RH; Fässler R; Schröder R; Noegel AA
    Mol Cell Biol; 2001 Jul; 21(13):4119-28. PubMed ID: 11390641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ANX7, a candidate tumor suppressor gene for prostate cancer.
    Srivastava M; Bubendorf L; Srikantan V; Fossom L; Nolan L; Glasman M; Leighton X; Fehrle W; Pittaluga S; Raffeld M; Koivisto P; Willi N; Gasser TC; Kononen J; Sauter G; Kallioniemi OP; Srivastava S; Pollard HB
    Proc Natl Acad Sci U S A; 2001 Apr; 98(8):4575-80. PubMed ID: 11287641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PTEN up-regulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer.
    Bandyopadhyay S; Pai SK; Hirota S; Hosobe S; Tsukada T; Miura K; Takano Y; Saito K; Commes T; Piquemal D; Watabe M; Gross S; Wang Y; Huggenvik J; Watabe K
    Cancer Res; 2004 Nov; 64(21):7655-60. PubMed ID: 15520163
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway.
    Du C; Yi X; Liu W; Han T; Liu Z; Ding Z; Zheng Z; Piao Y; Yuan J; Han Y; Xie M; Xie X
    BMC Cancer; 2014 Nov; 14():869. PubMed ID: 25417825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The significance of ANXA7 expression and its correlation with poor cellular differentiation and enhanced metastatic potential of gastric cancer.
    Hsu PI; Huang MS; Chen HC; Hsu PN; Lai TC; Wang JL; Lo GH; Lai KH; Tseng CJ; Hsiao M
    J Surg Oncol; 2008 Jun; 97(7):609-14. PubMed ID: 18449914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of ANXA7 GTPase activity by a small molecule promotes HMBOX1 translation of vascular endothelial cells in vitro and in vivo.
    Ma H; Su L; Zhang S; Kung H; Miao J
    Int J Biochem Cell Biol; 2016 Oct; 79():33-40. PubMed ID: 27506770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells.
    Asanuma H; Torigoe T; Kamiguchi K; Hirohashi Y; Ohmura T; Hirata K; Sato M; Sato N
    Cancer Res; 2005 Dec; 65(23):11018-25. PubMed ID: 16322251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Down-regulation of ANXA7 decreases metastatic potential of human hepatocellular carcinoma cells in vitro.
    Ibrahim MM; Sun MZ; Huang Y; Jun M; Jin Y; Yue D; Jiasheng W; Zhang J; Qazi AS; Sagoe K; Tang J
    Biomed Pharmacother; 2013 May; 67(4):285-91. PubMed ID: 23582794
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
    Block M; Gründker C; Fister S; Kubin J; Wilkens L; Mueller MD; Hemmerlein B; Emons G; Günthert AR
    Int J Oncol; 2012 Nov; 41(5):1845-54. PubMed ID: 22922893
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IkappaB-alpha that can be inhibited by the tumor suppressor PTEN.
    Pianetti S; Arsura M; Romieu-Mourez R; Coffey RJ; Sonenshein GE
    Oncogene; 2001 Mar; 20(11):1287-99. PubMed ID: 11313873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.